About - HUMA :

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Employees - 183, CEO - Dr. Laura E. Niklason M.D., Ph.D., Sector - Healthcare, Country - US, Market Cap - 800.63M

Altman ZScore(max is 10): -10.01, Piotroski Score(max is 10): 3, Working Capital: $2063000, Total Assets: $114764000, Retained Earnings: $-665075000, EBIT: -139652000, Total Liabilities: $178485000, Revenue: $10790000

AryaFin Target Price - $0.21 - Current Price $4.64 - Analyst Target Price $13.43

Stats & Key Metrics
TickerHUMA
IndexRUT
Curent Price 4.64
Change34.10%
Market Cap800.63M
Average Volume4.25M
Income-152.87M
Sales0.00M
Book Value/Share-0.53
Cash/Share0.12
Dividend Est-
Dividend TTM-
Dividend Ex-Date-
Employees183
Moving Avg 20days8.83%
Moving Avg 50days-4.39%
Moving Avg 200days-14.52%
Shares Outstanding119.84M
Earnings DateNov 08 BMO
Inst. Ownership27.90%
Key Ratios & Margins
Price/Earnings-
Forwad P/E-
PE Growth-
Price/Sales-
Price/Book-
Price/Cash38.66
Price/FCF-
Quick Ratio1.10
Current Ratio1.10
Debt/Equity-
Return on Assets-115.74%
Return on Equity-850.81%
Return on Investment-
Gross Margin-
Ops Margin-
Profit Margin-
RSI53.53
BETA(β)1.36
From 52week Low87.10%
From 52week High-53.46%
Earnings & Valuation
EPS-1.34
EPS next Year-0.86
EPS next Qtr-0.25
EPS this Year-26.44%
EPS next 5 Year-
EPS past 5 Year-
Sales past 5 Year0.00%
EPS Y/Y-54.99%
Sales Y/Y-100.00%
EPS Q/Q-30.64%
Sales Q/Q-
Sales Surprise-
EPS Surprise-32.48%
ATR(14)0.58
Perf Week13.17%
Perf Month5.22%
Perf Quarter-11.28%
Perf Year69.34%
Perf YTD63.38%
Target Price13.43

AryaFin Engine© - An AI FinTech Venture - 2024 Disclaimer